US AND INTERNATIONAL OPTIONS
BioGX has been on the forefront of COVID-19 testing, using its deep expertise with RNA virus tests – including human/avian/swine influenza and MERS-coronavirus – to develop our initial COVID-19 test.
Complete test in one tube
Capacity of 100,000 tests daily
BioGX offers a complete portfolio of COVID-19 tests for use around the world, each using its Sample-Ready™ approach combining all necessary reagents – mixed and lyophilized – in one tube and ready to run on the platform of your choice.
FDA EUA Tests/U.S.
Xfree™ COVID-19 Direct RT-PCR Test (FDA Emergency Use Authorized)
The world’s simplest high throughput RT-PCR test for COVID-19 has the potential to increase testing capacity by millions per week.
The Xfree™ COVID-19 Direct RT-PCR test is a complete test in a single vial, lyophilized in the trusted BioGX Sample-Ready™ format. The user would simply Just Add Water™, the patient sample, and run the test on a validated real-time PCR instrument.
BioGX SARS-CoV-2 Reagents for BD MAX™ System
An easy-to-use, rapid diagnostic test able to screen patients and health care workers for COVID-19. This test is run on the BD MAX™ System, a molecular diagnostic platform established in hundreds of laboratories in nearly every state across the U.S. Each BD MAX™ System is capable of analyzing hundreds of patient samples per day.
CE-IVD Marked Tests/International
BioGX COVID-19, Flu A, Flu B, RSV – RT-PCR for BD MAX™ System
The BioGX COVID-19, Flu A, Flu B, RSV – RT-PCR for BD MAX™ is a multiplex real-time reverse transcriptase, polymerase chain reaction (PCR) assay for use on the BD MAX™ platform for the combined qualitative detection of the presence of RNA from Influenza A, Influenza B, RSV A, RSV B, SARS-CoV-2 and a Sample Processing Control.
BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex
Product Ref. #400-058-E-HMP
A high-volume, real-time reverse transcriptase, PCR assay for use on multiple platforms, such as the BD MAX™, Bio-Rad CFX96 Touch™ and Applied Biosystems QuantStudio™ 5. The primer and probe sets are based on the U.S. Centers for Disease Control and Prevention (CDC) assay for specific detection of SARS-CoV-2 by amplifying two unique regions of the N gene (i.e., N1 and N2). Detection of the human RNase P gene serves as an endogenous Sample Processing Control (SPC).
New BioGX Xfree™ COVID-19 Direct RT-PCR
The New BioGX Xfree™ COVID-19 Direct RT-PCR is an extraction free Sample-Ready™ assay that does not require nucleic acid extraction, purification and concentration. The BioGX Xfree™ COVID-19 Direct RT-PCR enables a Sample-to-Answer solution on the most ubiquitous high capacity 96 & 384 well plate PCR instruments, dramatically increasing the lab’s potential for high volume throughput.